ReviewCancers2024
Ovarian Causes of Pseudomyxoma Peritonei (PMP)-A Literature Review.
Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 12 citations in OpenAlex.
- Exenterative Surgery in Advanced Pelvic Cancer: Survival Outcomes and an Exploratory Predictive Modeling Framework for Surgical Decision Support.Diagnostics (Basel, Switzerland) · 2026Article
- Pseudomyxoma peritonei presenting with pyloric obstruction: a case report.Journal of surgical case reports · 2026Article
- Pseudomyxoma Peritonei Presenting With Progressive Abdominal Distension and Abdominal Hernia: A Case Report.Cureus · 2026Article
- Research progress in the diagnosis and treatment of pseudomyxoma peritonei.World journal of surgical oncology · 2026Review
- High-volume mucinous ascites secondary to low-grade mucinous neoplasm arising in a mature cystic teratoma: a case report.AME case reports · 2026Article
- Huge mucinous ovarian borderline tumor: a case report.Journal of surgical case reports · 2025Article
- Magnetic Hydrogels as a Treatment for Oncological Pathologies.Journal of functional biomaterials · 2025Review
- Mucinous Carcinoma, Mucinous Borderline Tumor and Pseudomyxoma Ovarii in a Cystic Teratoma: A Histological Conundrum.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- The Evaluation, Diagnosis, and Management of Ovarian Cysts, Masses, and Their Complications in Fetuses, Infants, Children, and Adolescents.Healthcare (Basel, Switzerland) · 2025Review
- Status of and Challenges in Therapy of Mucinous Ovarian Cancer Associated with Pseudomyxoma Peritonei Syndrome: Review of Current Options and Future Treatment Trends.Life (Basel, Switzerland) · 2024Review
- Diagnostic Challenges and Treatment Options for Mucocle of the Appendix: A Comprehensive Review.Cureus · 2024Review
- A Review of Pseudomyxoma Peritonei: Insights Into Diagnosis, Management, and Prognosis.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPseudomyxoma peritonei (PMP) is a rare, progressive, slowly growing, inadequately understood neoplasm with a 5-year progression-free survival rate of as low as 48%. It is characterized by varying degrees of malignancy and the production of mucinous and gelatinous structures. Typically, the development of pseudomyxoma peritonei is associated with the rupture of appendiceal mucinous tumors and other gastrointestinal or ovarian mucinous tumors. The goal of our literature review was to identify various aspects that characterize the ovarian causes of pseudomyxoma peritonei. MATERIALS AND
methodsThe authors performed an extensive literature search between 1 February 2024 and 2 March 2024 on the following databases: Pubmed, Scopus, Oxford Journals, and Reaxys, and the findings were summarized into seven main clinical and paraclinical situations.
resultsAccording to our research, the main instances in which pseudomyxoma peritonei can be triggered by an ovarian cause are the following: (1) mucinous cystadenoma; (2) mucinous ovarian cancer; (3) colon cancer with ovarian metastasis; (4) malignant transformation of an ovarian primary mature cystic teratoma; (5) appendiceal mucocele with peritoneal dissemination mimicking an ovarian tumor with peritoneal carcinomatosis; (6) mucinous borderline tumor developing inside an ovarian teratoma; and (7) the association between a mucinous bilateral ovarian cancer and a colonic tumor.
conclusionsIn our study, we aimed to provide a comprehensive overview of the ovarian causes of pseudomyxoma peritonei, including its epidemiology, imagery characteristics, symptoms, current treatment, and promising future therapies, in the hopes of finding feasible solutions, as a lack of understanding of this mucus-secreting malignant disease increases the risk of delayed diagnosis or uncontrolled deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.